Key result
Variability in clopidogrel response is multifactorial and significantly influenced by CYP2C19 gene polymorphisms, particularly in Asian populations, leading to increased risk of adverse ischemic events.
Population
Patients receiving clopidogrel therapy, particularly those undergoing percutaneous coronary intervention and…
Design
Review
Authors
Loading...
Should not yet change clopidogrel use in Asians; leaves open whether genotype-guided therapy improves outcomes in trials.
Genetic variations, particularly in the CYP2C19 gene, significantly contribute to clopidogrel resistance and adverse ischemic outcomes, suggesting a potential role for pharmacogenetic testing in high-risk populations.
Bhat et al. (2016) conducted a review in Clopidogrel resistance in cardiovascular disease. Clopidogrel was evaluated. Variability in clopidogrel response is multifactorial and significantly influenced by CYP2C19 gene polymorphisms, particularly in Asian populations, leading to increased risk of adverse ischemic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: